LAUSR

Chronic intermittent hypoxia, a feature of sleep apnea, is a potent driver of solid tumor cancers and promotes lethal engraftment of malignant plasma cells in a mouse model. The objective of this study was to investigate if nighttime respiratory disturbances affect clinical outcomes in a multiple myeloma patient population. To do so, we prospectively assessed nighttime respiratory disturbance index (RDI) in 44 patients (27 male, 17 female) diagnosed with multiple myeloma at the University of Iowa Hospitals and Clinics. Following this assessment, we categorized patients by RDI and utilized electronic medical records to explore differences in routine myeloma clinical measures. We found 93% of the patients had an RDI equal to clinical sleep apnea. 39% of patients had a moderate or severe RDI. In comparing these patients to those with low RDI, there were no statistical differences in any clinical performance indicator. Additionally, there were no differences in disease symptoms, multiple myeloma staging, or antibody type between these groups. However, patients with a higher nighttime RDI were less likely to respond to induction chemotherapy (p=0.046), a predictor of poor disease prognosis. These data support the hypothesis that nighttime respiratory disturbances negatively impact multiple myeloma patients, but this impact may not be evident in routine clinical tests of patient performance. This research is supported by NIH award R01CA244271 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.